 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Albany Molecular Research, Inc.
 |
Albany Molecular Research, Inc. |
 |
 |
 |
NEWS FROM THE WIRES |
 |
Albany Molecular slightly raises 2001 guidance Aug 07 2001 01:31 PM PDT
RESEARCH ALERT-UBS Warburg starts Symyx, Albany Molecular Aug 02 2001 08:58 AM PDT
> More WIRE STORIES about this company
PROFILE |
 |
Albany Molecular Research provides contract chemistry R&D services to pharmaceutical and biotechnology firms. The company's services include drug discovery, medicinal chemistry, chemical development, analytical chemistry, and small-scale manufacturing. Drug companies outsource these operations to reduce development costs. Albany Molecular also conducts some proprietary lead discovery research, licensing potential therapies to other firms. It has one winner already: it owns the patent for fexofenadine HCl, the key ingredient in Aventis' antihistamine Allegra. About 45% of its revenues are from royalties paid by Aventis. CEO Thomas D'Ambra and his wife own about a quarter of the acquisitive company.
COMPETITION |
 |
ArQule, Inc. (ARQL)
Array BioPharma Inc. (ARRY)
Discovery Partners International, Inc. (DPII)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 37.40
1-Yr. Sales Growth: 70.0%
Employees: 379
Revenue per employee: $98,680.74
KEY PEOPLE |
 |
Thomas E. D'Ambra
CEO
David P. Waldek
CFO
CONTACT INFO |
 |
21 Corporate Circle
Albany, NY 12203
US
Phone: 518-464-0279
Fax: 518-464-0289
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |